For the year ending 2025-12-31, LCTX had -$5,030K decrease in cash & cash equivalents over the period. -$19,441K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss attributable to lineage | -63,533 |
| Net income (loss) attributable to noncontrolling interest | 166 |
| Issuance costs for common stock warrant liabilities | 183 |
| Loss on impairment of intangible asset | 14,840 |
| Loss on marketable equity securities, net | -8 |
| Accretion of income on marketable debt securities | 44 |
| Depreciation and amortization expense | 699 |
| Change in right-of-use assets and liabilities | -58 |
| Amortization of intangible assets | 0 |
| Stock-based compensation | 4,752 |
| Change in fair value of warrant liability | 35,727 |
| Deferred income tax benefit | -5,280 |
| Foreign currency remeasurement | 2,269 |
| Accounts receivable | 316 |
| Prepaid expenses and other current assets | -46 |
| Accounts payable and accrued liabilities | 2,271 |
| Deferred revenue | -6,111 |
| Net cash used in operating activities | -18,919 |
| Proceeds from the sale of marketable equity securities | 0 |
| Purchases of marketable debt securities | 14,935 |
| Maturities of marketable debt securities | 2,000 |
| Purchase of equipment | 522 |
| Net cash used in investing activities | -13,457 |
| Proceeds from employee options exercised | 1,250 |
| Proceeds from exercise of warrants | 319 |
| Common shares received and retired for employee taxes paid | 16 |
| Proceeds from sale of common shares, net of offering costs-At The Market | 20,908 |
| Proceeds from sale of common shares, net of offering costs-Direct Financing | 0 |
| Proceeds from sale of common shares, net of offering costs-Warrants Under Registered Direct Financing | 5,232 |
| Payment of financed insurance premium | 684 |
| Payment of finance lease liabilities | 59 |
| Net cash provided by financing activities | 26,950 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 396 |
| Net decrease (increase) in cash, cash equivalents and restricted cash | -5,030 |
| At beginning of the period | 46,354 |
| At end of the period | 41,324 |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)